0001225208-23-002038.txt : 20230215 0001225208-23-002038.hdr.sgml : 20230215 20230215174402 ACCESSION NUMBER: 0001225208-23-002038 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230214 FILED AS OF DATE: 20230215 DATE AS OF CHANGE: 20230215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mirviss Jeffrey B. CENTRAL INDEX KEY: 0001566094 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 23636548 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC CORPORATION STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0306 4 2023-02-14 0000885725 BOSTON SCIENTIFIC CORP BSX 0001566094 Mirviss Jeffrey B. 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 EVP&Pres, Periph Intervent Performance Share Units 2023-02-14 4 A 0 10430.0000 0.0000 A 2024-12-31 2024-12-31 Common Stock 10430.0000 10430.0000 D Restricted Stock Units 2023-02-14 4 A 0 11104.0000 0.0000 A 2027-02-14 Common Stock 11104.0000 11104.0000 D Stock Option (Right to Buy) 47.2800 2023-02-14 4 A 0 28893.0000 0.0000 A 2033-02-14 Common Stock 28893.0000 28893.0000 D Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. /s/ Susan Thompson, Attorney-in-Fact 2023-02-15